Increased tumor necrosis factor receptor 1 expression in human colorectal adenomas

Kunihiro Hosono, Eiji Yamada, Hiroki Endo, Hirokazu Takahashi, Masahiko Inamori, Yoshitaka Hippo, Hitoshi Nakagama, Atsushi Nakajima

Kunihiro Hosono, Eiji Yamada, Hiroki Endo, Hirokazu Takahashi, Masahiko Inamori, Yoshitaka Hippo, Hitoshi Nakagama, Atsushi Nakajima, Division of Gastroenterology, Yokohama City University School of Medicine, Yokohama 2360004, Japan
Yoshitaka Hippo, Hitoshi Nakagama, Division of Cancer Development System, National Cancer Center Research Institute, Tokyo 1040045, Japan

Author contributions: Hosono K performed most of the research and wrote the paper; Yamada E, Endo H and Takahashi H performed the endoscopies; Inamori M analyzed the data; Hippo Y, Nakagama H and Nakajima A were major contributors in revising the manuscript critically for important intellectual content.

Supported by Grant-in-Aid for Research from the Third-Term Comprehensive Control Research for Cancer Center of the Ministry of Health, Labor and Welfare, Japan; Grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan (KIBAN-B); and the “Collaborative Development of Innovative Seeds” Grant Program from the Japan Science and Technology Agency.

Correspondence to: Dr. Atsushi Nakajima, Professor, Division of Gastroenterology, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 2360004, Japan. nakajima-tky@umin.ac.jp
Telephone: +81-45-7872640 Fax: +81-45-7843546
Received: March 6, 2012 Revised: June 7, 2012 Accepted: June 15, 2012 Published online: October 14, 2012

Abstract

AIM: To determine the expression statuses of tumor necrosis factor (TNF)-α, its receptors (TNF-R) and downstream effector molecules in human colorectal adenomas.

METHODS: We measured the serum concentrations of TNF-α and its receptors in 62 colorectal adenoma patients and 34 healthy controls. The protein expression of TNF-α, TNF-R1, TNF-R2 and downstream signals of the TNF receptors, such as c-Jun N-terminal kinase (JNK), nuclear factor-κ B and caspase-3, were also investigated in human colorectal adenomas and in normal colorectal mucosal tissues by immunohistochemistry. Immunofluorescence confocal microscopy was used to investigate the consistency of expression of TNF-R1 and phospho-JNK (p-JNK).

RESULTS: The serum levels of soluble TNF-R1 (sTNF-R1) in adenoma patients were significantly higher than in the control group (3.67 ± 0.86 ng/mL vs 1.57 ± 0.72 ng/mL, P < 0.001). Receiver operating characteristic analysis revealed the high diagnostic sensitivity of TNF-R1 measurements (AUC was 0.928) for the diagnosis of adenoma, and the best cut-off level of TNF-R1 was 2.08 ng/mL, with a sensitivity of 93.4% and a specificity of 82.4%. There were no significant differences in the serum levels of TNF-α or sTNF-R2 between the two groups. Immunohistochemistry showed high levels of TNF-R1 and p-JNK expression in the epithelial cells of adenomas. Furthermore, a high incidence of co-localization of TNF-R1 and p-JNK was identified in adenoma tissue.

CONCLUSION: TNF-R1 may be a promising biomarker of colorectal adenoma, and it may also play an important role in the very early stages of colorectal carcinogenesis.

© 2012 Baishideng. All rights reserved.

Key words: Tumor necrosis factor-α; Tumor necrosis factor receptor 1; c-Jun N-terminal kinase; Colorectal adenoma; Biomarker

Peer reviewers: Peter Laszlo Lakatos, MD, PhD, 1st Department of Medicine, Semmelweis University, Koranyi SZA, H1083 Budapest, Hungary; Annika Lindblom, Professor, Molecular Medicine and Surgery, Karolinska Institutet, S17176 Stockholm, Sweden; Manuel Romero-Gomez, Professor, Department of Medicine, University of Sevilla, Avda. de Bellavista, 41014 Seville, Spain
Hosono K, Yamada E, Endo H, Takahashi H, Inamori M, Hippo Y, Nakagama H, Nakajima A. Increased tumor necrosis factor receptor 1 expression in human colorectal adenomas. World J Gastroenterol 2012; 18(38): 5360-5368. Available from: URL: http://www.wjgnet.com/1007-9327/full/v18/i38/5360.htm DOI: http://dx.doi.org/10.3748/wjg.v18.i38.5360

INTRODUCTION

The proinflammatory cytokine, tumor necrosis factor (TNF), plays an important role in diverse cellular events, such as the induction of other cytokines’ expression, cell proliferation, differentiation, necrosis and apoptosis[1,2]. Many of the TNF-induced cellular responses are mediated by one of two specific cellular membrane receptors, tumor necrosis factor receptor 1 (TNF-R1) and TNF-R2, both of which belong to the TNF receptor superfamily[3]. In response to TNF treatment, activation of nuclear factor-κ B (NF-κB), a transcription factor, as well as mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase, p38, and c-Jun N-terminal kinase (JNK) have been reported in most cell types and, in some cases, after apoptosis or necrosis had been induced[4,5].

Overexpression of TNF-α and its receptors often accompanies tumor development and progression, and their important role in the pathogenesis of cancer is now increasingly recognized. Several studies have reported on the status of TNF-α expression in various malignancies. For example, TNF-α mRNA and protein have been detected in both malignant and stromal cells in human ovarian cancer biopsies[6,7]. The plasma levels of TNF-α have been reported to be increased in some cancer patients, especially those with poor prognoses[8-11]. Blood TNF-α concentrations have been reported to be higher in prostate cancer patients with advanced, cachectic disease[12]. These findings suggest that TNF-α might also have an important role in carcinogenesis. We now know that many of the cells and mediators of inflammation that have been detected in human and experimental cancers and inflammatory conditions increase the risk of cancer development[13-16]. There is strong evidence to suggest that cancer-related inflammation aids in the proliferation and survival of malignant cells, stimulates angiogenesis and metastasis[17-19], subverts adaptive immunity[20-22], and modulates their responses to hormones and chemotherapy[23,24].

In colon cancer, TNF-α has demonstrated to promote carcinogenesis, and anti-TNF-α drugs are being used therapeutically[25,26]. Moreover, serum TNF-α is known to serve as an important pathophysiologic marker for the presence and severity of inflammatory bowel disease[27]. However, TNF-α has a short half-life (20 min); therefore, accurate measurement of the blood levels is difficult[28]. There is some debate about whether TNF-α can actually be measured using some sort of physiologically active substance[28,29]. On the other hand, TNF-R1 and TNF-R2 are released into the blood as soluble TNF-R1 (sTNF-R1) and soluble TNF-R2 (sTNF-R2) after proteolysis of their extracellular domains in response to activators, including TNF-α itself[30,31]. Their presence in the peripheral blood is reflective of an inflammatory response occurring within the body. sTNF-R1 and sTNF-R2 also have very long half-lives; thus, they are more stable than TNF-α[32,33]. These receptors may provide better serum biomarkers than TNF-α. Spoettl et al[34] found that serum sTNF-R1 levels were significantly increased in ulcerative colitis (UC) patients compared with that of healthy controls. However, there have been few reports of the association between TNF-R1 and TNF-R2 and sporadically occurring colorectal neoplasms[35]. Thus, the association of these receptors with the risk of colorectal adenoma has not yet been fully clarified. The aim of this study was to investigate the serum levels of TNF-α, sTNF-R1 and sTNF-R2 in adenoma patients and also to investigate the expressions of downstream molecules in the TNF-α signaling pathway, including TNF-R1, TNF-R2, JNK, NF-κB and caspase-3 in adenoma tissues in comparison to those in normal colorectal mucosa.

MATERIALS AND METHODS

Patients

The study population consisted of 62 consecutive patients with colorectal adenoma who underwent colonoscopy from January 2008 to January 2009 at the Division of Gastroenterology, Yokohama City University School of Medicine. Patients with concomitant diseases, including infectious diseases, inflammatory bowel diseases, autoimmune conditions, allergy or asthma, that were likely to elevate serum TNF-α levels were excluded from the study. The patients ranged in age from 54 to 86 years (mean ± SD: 67.7 ± 8.2 years) and consisted of 39 males and 23 females. The control group consisted of 34 healthy people, matched for age. The control group consisted of people undergoing colonoscopy after positive fecal occult blood test but not found to have adenomas. The study was carried out in accordance with the Declaration of Helsinki (revised 1989) and with the approval of the Ethics Committee of Yokohama City University School of Medicine. Informed consent was obtained from each patient participating in this study and for the use of the obtained data for research purposes.

Serum samples

Before colonoscopy, blood samples were obtained from all participants after an overnight fast to determine the serum concentrations of TNF-α, sTNF-R1 and sTNF-R2. The blood samples were centrifuged at 800 g for 5 min. Serum was separated as soon as possible from the clot of red blood cells by centrifugation to avoid TNF-α production by the blood cells, which would have led to falsely increased values[36]. Then, the serum specimens were stored at -80 ℃ until the biochemical analyses.
Biochemical determinations
Serum concentrations of human TNF-α, sTNF-R1 and sTNF-R2 were determined by enzyme-linked immunosorbent assay (ELISA) kit (R and D Systems Inc., Minneapolis, MN, United States). The minimum limits of detection of the assay were as follows: TNF-α, 1.6 pg/mL; sTNF-R1, 0.77 pg/mL; and sTNF-R2, 0.6 pg/mL. The tests were carried out as described in the product manuals.

Immunohistochemical analysis
Immunohistochemical analysis was performed in the adenomatous polyps retrieved from the study patients (n = 62). Adenomatous polyps removed during colonoscopy, together with normal colorectal mucosal biopsies from the same patients when possible, were examined. Four-micrometer sections were prepared from the formalin-fixed, paraffin-embedded tissues and mounted on slides coated with polylysine. We examined only sporadically occurring polyps by excluding specimens from patients with familial adenomatous polyposis (FAP) or hereditary non-polyposis coli (HNPPC). The protein expression levels were determined in all 62 normal and colorectal adenomatous tissue sections by immunohistochemistry. Sections were deparaffinized in xylene and rehydrated. The sections were then heated in a 750 W microwave three times for 7 min. Inhibition of endogenous peroxidase activity was performed by treating sections with 3% hydrogen peroxide for 10 min. After washing three times with Tris-Buffered Saline (TBS), the blocking of non-specific interactions was accomplished by incubating the samples with blocking serum for 30 min at room temperature. Sections were then probed with the primary antibodies (Table 1) and subsequently incubated with the Histofine simple stain max PO kit for 30 min (Nichirei Laboratories, Tokyo, Japan) in accordance with the manufacturer’s instructions. The signals were visualized by treatment with diaminobenzidine (peroxidase substrate kit, Vector Laboratories, Burlington, CA, United States), and the sections were counterstained with hematoxylin. Six random microscopic fields per sample of approximately 250 cells were counted at a magnification of 400× under a bright-field microscope. The results were expressed as the percentage of positive cells with separating epithelial cells and stromal cells.

Immunofluorescence confocal microscopy
For immunofluorescence studies, the sections were stained with anti-TNF-R1 rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, United States) at a dilution of 1:50, anti-TNF-R2 rabbit polyclonal antibody (Santa Cruz Biotechnology) at a dilution of 1:50, and anti-p-JNK mouse monoclonal antibody at Thr 183 and Tyr 185 (Santa Cruz Biotechnology) at a dilution 1:50. After thorough washes in TBS, sections were incubated with their respective Alexa594-conjugated anti-rabbit IgG secondary antibodies (Invitrogen, Carlsbad, CA, United States) or Alexa488-conjugated anti-mouse IgG secondary antibodies (Invitrogen) for 1 h, washed, and mounted.

The confocal imaging was carried out on a FV1000-D (Olympus, Tokyo, Japan) confocal laser scanning microscope. Excitation and detection of the samples were carried out in sequential modes to avoid overlapping of signals. Sections were scanned simultaneously at both wavelengths (488/594 nm) with appropriate laser intensity, confocal aperture, and gain. The Black-level setting was kept constant for all samples.

Statistical analysis
Data were expressed as the mean ± SD unless otherwise indicated. The significances of the differences in clinical characteristics between patients with adenomas and controls were evaluated by the χ2-test for categorical variables and Welch’s test for continuous variables. One-way analysis of variance was performed to compare the prevalence of each variable between groups. To assess the diagnostic sensitivity and specificity of the sTNF-R1 and sTNF-R2 measurements, receiver operating characteristic (ROC) curve analysis was performed. P < 0.05 was considered to indicate statistical significance.

RESULTS
Biochemical determinations
Table 2 shows a comparison of the clinical data and laboratory parameters between the 62 patients with adenoma and the 34 normal controls. No differences in
the age, sex or body mass index were found between the two studied groups. The mean serum levels of sTNF-R1 were significantly higher in the adenoma patients compared to the control group patients. On the other hand, there were no significant differences in the serum levels of TNF-α or sTNF-R2 between the two groups. Linear contrast analysis was conducted to evaluate the correlation between each variable and the number of adenomas per person (Table 3). The serum levels of sTNF-R1 were positively correlated with the number of adenomas in the colorectum (P < 0.001). As assessed by nonparametric analysis of the ROC curves, sTNF-R1 measurements showed a high diagnostic sensitivity at a value of 0.928 (Figure 1). The best cut-off level for TNF-R1 as 2.08 ng/mL, which showed a specificity of 93.4% and a specificity of 82.4%.

**Immunohistochemical analysis**

Immunohistochemistry showed varying expression intensities of TNF-α, TNF-R1, TNF-R2, p-JNK, NF-kB and caspase-3 in different areas of the samples. The expression of TNF-α in the stromal area of adenomas was significantly higher than that in the stromal areas of the normal mucosa (P < 0.05); however, the expression of TNF-α in the epithelial cells of adenomas was not as high as that in the epithelial cells of the normal mucosa (Figure 2). The expression of TNF-R1 in the epithelial cells of the adenomas was significantly higher than that in the epithelial cells of the normal mucosa (P < 0.05); however, in the stromal areas, the expression of TNF-R1 was equivalent between the adenomas and the normal mucosa. No significant difference in the expression of TNF-R2 was noted in either the epithelial cells or the stromal areas between the adenomas and the normal mucosa. In relation to the expression of the downstream molecules in the TNF-α signaling pathway, the expression of p-JNK in both the epithelial cells and stromal areas of the adenoma were significantly higher than those in the normal mucosa (P < 0.05) (Figure 3). However, there were no significant differences in the expressions of NF-κB or caspase-3 in either the epithelial cells or stromal areas between the adenomas and the normal mucosa.

To investigate the consistency of TNF-R1 and p-JNK expression, we performed immunofluorescence staining of the adenoma tissues, because the results of immunochemistry revealed high levels of TNF-R1 and p-JNK expression in the epithelial cells of the adenomas. The results revealed expression of TNF-R1 and p-JNK co-localized predominantly in the epithelial cells of the adenomas. Merged images of TNF-R1 and p-JNK immunofluorescence staining demonstrated this co-localization (Figure 4). On the other hand, the expression of TNF-R2 was localized predominantly to the stromal area of the adenomas, and merged images of TNF-R2 and p-JNK immunofluorescence staining showed a lack of co-localization.

**DISCUSSION**

This is the first study to show marked changes in the expression levels of TNF-R1 in colorectal adenoma tissues. The serum sTNF-R1 levels were also significantly higher in colorectal adenoma patients than in the control subjects. To evaluate the possible usefulness of TNF-R1 as a biomarker for colorectal adenoma, we evaluated the correlation between the number of adenomas in the colorectum and the serum sTNF-R1 level. The results showed that the serum sTNF-R1 level positively correlated with the number of colorectal adenomas. A ROC analysis revealed the high diagnostic sensitivity and specificity of sTNF-R1 measurements for diagnosis of colorectal adenoma. These results may suggest that TNF-R1 is a promising biomarker for colorectal adenomas. In addition, our results agreed with the Kaminska et al study, which showed that sTNF-R1 had the highest diagnostic sensitivity in colorectal cancer patients. Other previous reports have shown a high diagnostic and prognostic accuracy of serum sTNF-R1 levels for various diseases. Determination of the TNF-R1 levels in several body fluids, including the serum, provides valuable insight into a variety of pathological conditions. For example, in cervical adenocarcinoma patients, serum sTNF-R1 is reported to be a useful marker, especially in the early stages of disease. In patients with breast cancer, serum sTNF-R1 is considered to be an independent and clinically useful

**Table 3** Association between the measured biochemical parameters and the number of colorectal adenomas per person

|                         | ≤ 3 (n = 34) | ≥ 4 (n = 28) | P value |
|-------------------------|-------------|-------------|---------|
| TNF-α (pg/mL)           | 5.63 ± 1.3  | 4.31 ± 1.9  | 4.95 ± 2.0 | NS     |
| sTNF-R1 (ng/mL)         | 1.57 ± 0.72 | 3.37 ± 0.93 | 4.05 ± 0.55 | < 0.001|
| sTNF-R2 (ng/mL)         | 2.72 ± 1.15 | 3.13 ± 0.88 | 3.04 ± 0.95 | NS     |

Values are expressed as the mean ± SD; P < 0.05 denoted significance. NS: Non-significant; TNF-α: Tumor necrosis factor-α; sTNF-R1/2: Soluble tumor necrosis factor receptor 1/2.

![Figure 1](image-url)
TNFR-1 is an important member of the death receptor family, which is capable of inducing apoptotic cell death\cite{40}. In addition to its involvement in apoptotic signaling, TNF-R1 has been widely studied because it is a dual-role receptor. In addition to inducing apoptosis, it also has the ability to transduce cell survival signals. When TNF-R1 transduces cell survival signals, TNFR-associated factor 2 (TRAF-2) is recruited to the complex, which inhibits apoptosis via the cytoplasmic inhibitor of apoptosis protein (cIAP). The binding of TRAF-2 initiates a sequence of phosphorylation steps resulting in the activation of cFos/cJun transcription factors via MAPK and JNK\cite{41}. The cFos/cJun transcription factors induce transcription of antiapoptotic, proliferative, immunomodulatory, and inflammatory genes.

TNF-α is a major mediator of cancer-related inflammation\cite{13,42}, and most of the pro-tumor actions of TNF-α appear to be mediated by TNF-R1. Mouse experiments have revealed that the development of primary cancers and metastases is attenuated in mice deficient in TNF-R1. For example, TNF-R1-/- mice are resistant to DMBA-TPA carcinogenesis, as are TNF-α-/- mice\cite{43}. Experimental formation of lung and liver metastases was attenuated in TNF-R1-/- mice compared with that in their normal counterparts\cite{44,45}. In wild-type mice with bone marrow cells repopulated using cells from TNF-R1-/- mice, the likelihood of colitis and colon cancer development was reduced\cite{46} suggesting that TNF-α in the tumor microenvironment enhanced tumor development through its actions on TNF-R1-positive myeloid cells. In various pathologic states, it has been reported that the production and release of TNF-R1 may mediate host responses and determine the course and outcome of the disease by binding with TNF-α and competing with cell surface receptors.

Figure 2  Immunohistochemical analyses in the normal colorectal mucosa and adenoma tissues. A: Tumor necrosis factor (TNF)-α expression in the normal colorectal mucosa; B: TNF-α expression in the adenoma tissues; C: The percentage of TNF-α-positive cells; D: Tumor necrosis factor-receptor 1 (TNF-R1) expres- sion in the normal colorectal mucosa; E: TNF-R1 expression in the adenoma tissues; F: The percentage of TNF-R1-positive cells; G: TNF-R2 expression in the normal colorectal mucosa; H: TNF-R2 expression in the adenoma tissues; I: The percentage of TNF-R2-positive cells. Box plots display median values and interquartile ranges (C, F, I). The non-outlier range is also shown. \(P < 0.05\) between NM and AD in stromal of TNF-α; \(P < 0.05\) between NM and AD in epithelial of TNF-R1. NS: Non-significant; NM: Normal mucosa; AD: Adenoma.
In addition to the systematic analysis of serum sTNF-R1, we also investigated, by immunohistochemical analysis, the local expressions of downstream molecules in the TNF-α signaling pathway in normal colorectal mucosa and adenoma tissues. The results revealed high levels of TNF-R1 and p-JNK expression in the epithelial cells of adenomas. Moreover, we identified co-localization of TNF-R1 and p-JNK in adenomas by immunofluorescence confocal microscopy. In the past, expression of p-JNK in adenomas has only been described by Hardwick et al. [47]. These authors found that the expression of p-JNK was observed mainly in stromal T-lymphocytes, and epithelial cells were not stained. The discrepancy in our results was presumably due to differences in the immunohistochemical staining protocol used. The Hardwick study used phosphate-buffered saline (PBS) as the wash buffer, while we used TBS. Additionally, different antibodies were used in the two studies, which may have resulted in the absence of phospho-JNK staining in the epithelial cells of their study.

Our results suggest that the TNF-R1/p-JNK pathway is upregulated in adenomas and that this pathway may play an important role in adenoma formation, which represents the very early stages of colorectal carcinogenesis because this pathway is not upregulated in the normal colorectal mucosa. Expression of JNK in colon cancer has already received some attention [48,49]; studies have found increased activity of JNK in both rat models of colon cancer and human colorectal tumors. In addition, Zhang et al. [50] indicated that the TNF-R1/JNK signaling cascade can functionally promote tumorigenesis of human epithelial cancers, such as squamous cell carcinomas. Moreover, a recent study conducted by our group showed that JNK/c-Jun may play an important role in promoting colorectal carcinogenesis and epithelial cell proliferation under high-fat dietary conditions [51].
Our study had several important novelties. We showed for the first time that the serum levels of sTNF-R1 may have high diagnostic sensitivity and specificity as a biomarker for colorectal adenoma. Second, TNF-R1 was relatively undetectable in the normal colorectal mucosa, whereas adenomas showed high expression levels of TNF-R1. In addition, co-expression of p-JNK with TNF-R1 was observed in adenomas, although a previous study reported that the epithelial cells of adenoma showed a lack of p-JNK staining\(^{[47]}\). These results suggest that the TNF-R1/JNK pathway may play an important role in the development/progression of colorectal adenoma.

The present study also had some limitations. First, our research target was colorectal adenoma and not colorectal cancer. Thus, further studies targeting colorectal cancer are needed. Secondly, the control population was small. Third, different cell death receptors are able to activate JNK. Therefore, the increased p-JNK expression in adenoma tissue may be related to TNF-R1 or other effectors. The expression of cell death receptors may also be altered in inflammatory cells, which may certainly be involved in cancer progression. Fourth, it was considered that TNF-R1 may directly stimulate JNK activation, but this would also be difficult to prove.

In conclusion, this is the first study to report elevated serum levels of sTNF-R1 in patients with adenomas compared to a control group. We also found, by immunohistochemical analysis, enhanced expression of TNF-R1 in colorectal adenomas. These results suggest that TNF-R1 may not only be a promising biomarker of colorectal adenoma but also plays an important role in the very early stages of colorectal carcinogenesis. More studies are needed to elucidate the exact functions of TNF-R1 in colorectal adenomas.

**ACKNOWLEDGMENTS**

We thank Machiko Hiraga for her technical assistance.

**COMMENTS**

**Background**

The proinflammatory cytokine, tumor necrosis factor (TNF-α), is a major mediator of cancer-related inflammation. However, little has been reported on the relationship between TNF-α and sporadically occurring colorectal neoplasms. Studies on human colorectal adenoma were performed to determine the expression statuses of TNF-α and its receptors.

**Research frontiers**

Overexpression of TNF-α and its receptors often accompanies tumor development and progression, and their important role in the pathogenesis of cancer is
now increasingly recognized.

Innovations and breakthroughs

The authors show, for the first time, that the serum levels of tumor necrosis factor-receptor 1 (TNF-R1) may have high diagnostic sensitivity and specificity as a biomarker of colorectal adenoma. TNF-R1 was hardly detected in the normal colorectal mucosa, whereas adenomas showed high expression levels of TNF-R1. In addition, co-expression of phospho-c-Jun N-terminal kinase (p-JNK) with TNF-R1 was observed in adenomas. These results suggest that the TNF-R1/JNK pathway may play an important role in the development/progression of colorectal adenoma.

Applications

TNF-R1 may be a promising biomarker of colorectal adenoma, and further studies may show that TNF-R1 expression can be used to screen for adenomas in patients as an alternative or in addition to hemoccult screening or colonoscopy screening.

Terminology

TNF-R1 belongs to the TNF receptor superfamily. In response to TNF treatment, activation of the transcription factor nuclear factor-κB and mitogen-activated protein kinase, as well as Extracellular Signal-regulated Kinase, p38, and JNK, has been reported in most types of cells and, in some cases, apoptosis or necrosis was also induced.

Peer review

This is an interesting study investigating the importance of TNF-R1/JNK co-expression in colorectal adenoma. The major finding of the study was that serum levels of TNF-R1 were higher in patients with colorectal adenomas, while expression in colorectal adenoma. The major finding of the study was that TNF-R1/JNK pathway may play an important role in the development/progression of colorectal adenoma.

REFERENCES

1. Rothe J, Gehr G, Loetscher H, Lesslauer W. Tumor necrosis factor receptors—structure and function. Immunol Res 1992; 11: 81-90
2. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol 1993; 9: 317-343
3. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today 1992; 13: 151-153
4. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959-962
5. Liu ZG, Han J. Cellular responses to tumor necrosis factor. Curr Issues Mol Biol 2001; 3: 79-90
6. Naylor MS, Malik ST, Stamp GW, Jobling T, Balkwill FR. Tumor necrosis factor receptors and its receptors in human colorectal cancer. J Clin Invest 1993; 91: 2194-2206
7. Karayianakis AJ, Syrigos KN, Polychronidis A, Pitakoudis M, Bounovas A, Simopoulos K. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients. Anticancer Res 2001; 21: 1355-1358
8. Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, Kishimoto T, Nakatani T. Interleukin-6, tumor necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 2002; 86: 1396-1400
9. Ferrajoli A, Keating MJ, Manoukian S, Giles FJ, Dey A, Estrov Z, Roller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002; 100: 1215-1219
10. Bozuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdoğan M, Artar M, Altunbaş H, Akan I, Savas B. Tumor necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 2004; 27: 58-65
11. Pfitzenmaier J, Vessella R, Higano CS, Noteboom JL, Wallace D, Corey E. Evaluation of cytokine levels in capecitabine patients with prostate carcinoma. Cancer 2003; 97: 1211-1216
12. Sethi G, Sung B, Aggarwal BB. TNF: a master switch for inflammation to cancer. Front Biotechnol 2008; 13: 5094-5107
13. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545
14. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-217
15. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444
16. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, Gould D, Ayyan A, Balkwill F. Tumor necrosis factor receptors induce Smad3 phosphorylation and enhanced polarized inflammation in epithelial ovarian cancer cells. Cancer Res 2007; 67: 585-592
17. Egberts JH, Cloosters V, Noack A, Schniewind B, Thon L, Klose S, Kettler B, von Förstner C, Kneitz C, Tepel J, Adam D, Wajant H, Kalthoff H, Trauzold A. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2008; 68: 1443-1450
18. Zins K, Abraham D, Sioud M, Aharinejad S. Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 2007; 67: 1038-1045
19. Kashii Y, Giorda R, Herberman RB, Whiteside TL, Vujanovic NL. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells. J Immunol 1999; 163: 5388-5366
20. Prévost-Blondel A, Roth E, Rosenthal FM, Pircher H. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol 2000; 164: 3645-3651
21. Baxevanis CN, Voutsas IF, Tsigilison OE, Tsiatsis ML, Gritzapis AD, Papamichail M. Compromised anti-tumor responses in tumor necrosis factor alpha knockout mice. Eur J Immunol 2000; 30: 1957-1966
22. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. Tumor necrosis factor-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer 2000; 82: 973-980
23. Seynhaeve AL, Hoving S, Schipper D, Vermeulen CE, de Wiel-Ambagtssheer G, van Tiel ST, Eggermont AM, Ten Hagen TL. Tumor necrosis factor alpha mediates homogenous distribution of liposomes in murine melanoma that contributes to a better tumor response. Cancer Res 2007; 67: 9455-9462
24. Waldner MJ, Neurath MF. Cytokines in colitis associated cancer: potential drug targets? Inflamm Allergy Drug Targets 2008; 7: 187-194
25. Rizzo A, Pallone F, Monteleone G, Fantini MC. Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol 2011; 17: 3092-3100
26. Komatsu M, Kobayashi D, Saito K, Furuya D, Yagihashi A, Arakawa H, Tsuji N, Sakamaki S, Niitsu Y, Watanabe N. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001; 47: 1297-1301
27. Duncome AS, Brenner MK. Is circulating tumor necrosis factor bioactive? N Engl J Med 1988; 319: 1227-1228
28. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor receptor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415
29. Nophar Y, Kemper O, Brzekebusch C, Englemann H, Zwang R, Aderka D, Holtmann H, Wallach D. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the
Hosono K et al. TNF-R1 expression in human colorectal adenomas

...type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990; 9: 3269-3278

Wallach D, Engelmann H, Nophar Y, Aderka D, Kemper O, Hornik V, Holtmann H, Brakebusch C. Soluble and cell surface receptors for tumor necrosis factor. Agents Actions Suppl 1991; 35: 51-57

Aderka D, Engelmann H, Shemer-Avni Y, Hornik V, Galil A, Sarov B, Wallach D. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res 1992; 11: 157-159

Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wurzelmann JI, Murray SC, Woosley JA, Tilz GP, Zangerle R, Baier-Bitterlich G, Wa...